Loading...
XSHE
002099
Market cap1.38bUSD
Dec 05, Last price  
6.14CNY
1D
-0.65%
1Q
3.19%
Jan 2017
-27.59%
IPO
125.32%
Name

Zhejiang Hisoar Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002099 chart
P/E
P/S
5.02
EPS
Div Yield, %
Shrs. gr., 5y
-0.42%
Rev. gr., 5y
-8.00%
Revenues
1.94b
-10.75%
690,764,236770,205,8801,034,886,0221,062,995,967893,369,0471,074,589,2591,298,437,7631,145,374,3771,160,690,6971,319,135,7372,464,495,5332,433,862,0712,308,922,1702,718,608,7962,941,412,7702,471,386,6262,484,828,4372,704,144,0462,171,886,8691,938,465,657
Net income
-330m
49,596,01552,112,94931,050,88225,597,25330,301,75885,628,270105,064,38622,780,419053,519,259516,587,190225,018,251342,217,155605,003,820770,782,185319,715,24695,229,60088,013,7290-330,267,195
CFO
175m
-27.31%
36,071,82361,882,54451,140,58830,607,75998,380,566180,879,96592,619,740180,727,34160,850,636191,561,807462,163,337629,417,200102,676,414791,449,237612,399,095533,869,722102,360,758116,092,038240,536,591174,834,870
Dividend
May 24, 20230.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Hisoar Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells fine chemicals and special raw drugs in China and internationally. It offers antibiotic, anti-virus, cardiovascular, sugar-reducing, and other materials; and medicine intermediates, and other customized and processed products, such as clindamycin, 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, voglibose, eclindamycin, 4-AA iso-carbapenem, thiamphenicol, florfenicol, voglibose, etc. It also exports its products. The company was founded in 1966 and is based in Taizhou, China.
IPO date
Dec 26, 2006
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT